AMPH

Amphastar Pharmaceuticals, Inc.
$18.66
-0.63 (-3.27%)
Mkt Cap 815.72M
Volume 212,709
52W Range 16.65-31.26
Sector Healthcare
Beta 0.89
EPS (TTM) 1.71
P/E Ratio 10.82
Revenue (TTM) 720.53M
Rev Growth (5Y) +15.5%
EPS Growth (5Y) +134.2%
AlphaVal · Fair Value
What we estimate one share is worth
$25.11
Undervalued moderate signal
26.3% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
B+
Platform & Compounding FCF
75.9 / 100 composite
A platform business that compounds free cash flow — graded A–F vs. similar companies.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 719.89M 731.97M 644.39M 498.99M 437.77M 349.85M 322.36M 294.67M 240.18M 255.16M 251.52M 210.46M
Net Income 98.09M 159.52M 137.54M 91.39M 62.12M 1.40M 48.94M (5.74M) 4.51M 10.53M (2.79M) (10.70M)
EPS 2.10 3.29 2.85 1.88 1.30 0.03 1.04 -0.12 0.10 0.23 -0.06 -0.25
Free Cash Flow 121.23M 172.34M 145.34M 65.15M 70.54M 23.41M 207,000 (8.62M) 4.11M 17.18M (5.37M) 553,000
FCF / Share 2.59 3.56 3.01 1.34 1.48 0.50 0.00 -0.19 0.09 0.38 -0.12 0.01
Operating CF 156.12M 213.39M 183.50M 89.18M 97.99M 57.27M 41.76M 38.19M 39.21M 38.56M 10.68M 21.05M
Total Assets 1.63B 1.58B 1.51B 741.99M 671.53M 631.24M 586.97M 513.56M 454.67M 427.74M 390.14M 389.37M
Total Debt 656.00M 650.55M 623.64M 102.58M 104.66M 67.27M 66.62M 50.21M 47.16M 37.72M 41.10M 43.70M
Cash & Equiv 170.18M 151.61M 144.30M 156.10M 126.35M 92.64M 75.55M 86.34M 65.59M 72.35M 66.07M 67.83M
Book Value 788.80M 732.30M 639.42M 528.66M 445.52M 402.31M 381.37M 332.44M 337.33M 329.25M 295.51M 281.86M
Return on Equity 0.12 0.22 0.22 0.17 0.14 0.00 0.13 -0.02 0.01 0.03 -0.01 -0.04
AMPH News
New Strong Sell Stocks for June 23rd
Jun 23, 2026 02:16 AM · zacks.com
Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth
Jun 10, 2026 03:09 PM · marketbeat.com
Amphastar Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Jun 08, 2026 04:19 AM · globenewswire.com
Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag
Jun 03, 2026 08:02 PM · marketbeat.com
Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference
May 27, 2026 02:00 AM · accessnewswire.com
Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook
May 13, 2026 10:06 PM · marketbeat.com
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
May 13, 2026 04:50 PM · seekingalpha.com
Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcript
May 08, 2026 02:41 AM · seekingalpha.com
Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics
May 07, 2026 05:01 PM · zacks.com
Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimates
May 07, 2026 02:55 PM · zacks.com